Isis Ricaño-Ponce

Dr. Isis Ricaño-Ponce

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2011 in Nature Genetics
Verified
Journal Article
Open access
PDF file
S(Spanish Consortium on the Genetics of Coeliac Disease (CEGEC)
Spanish Consortium on the Genetics of Coeliac Disease (CEGEC)
GTGosia Trynka
Gosia Trynka
PGPreventCD Study Group
PreventCD Study Group
W(Wellcome Trust Case Control Consortium (WTCCC)
Wellcome Trust Case Control Consortium (WTCCC)
KHKaren A Hunt
Karen A Hunt
DHDavid A van Heel
David A van Heel
David van Heel, Cisca Wijmenga and colleagues used a custom, high-density genotyping chip to examine 183 immune-related loci for their role in celiac disease. They report 13 new regions associated with celiac disease risk, identify multiple independent signals at several loci and refine the localization of many previously reported risk signals. Using variants from the 1000 Genomes Project pilot European CEU dataset and data from additional resequencing studies, we densely genotyped 183 non-HLA risk loci previously associated with immune-mediated diseases in 12,041 individuals with celiac disease (cases) and 12,228 controls. We identified 13 new celiac disease risk loci reaching genome-wide significance, bringing the number of known loci (including the HLA locus) to 40. We found multiple independent association signals at over one-third of these loci, a finding that is attributable to a combination of common, low-frequency and rare genetic variants. Compared to previously available data such as those from HapMap3, our dense genotyping in a large sample collection provided a higher resolution of the pattern of linkage disequilibrium and suggested localization of many signals to finer scale regions. In particular, 29 of the 54 fine-mapped signals seemed to be localized to single genes and, in some instances, to gene regulatory elements. Altogether, we define the complex genetic architecture of the risk regions of and refine the risk signals for celiac disease, providing the next step toward uncovering the causal mechanisms of the disease.

21 April 2013 in Nature Genetics
Verified
Journal Article
Open access
PDF file
TCThe UK-PSCSC Consortium
The UK-PSCSC Consortium
JLJimmy Z Liu
Jimmy Z Liu
TCThe International IBD Genetics Consortium
The International IBD Genetics Consortium
TGThe International PSC Study Group
The International PSC Study Group
JHJohannes Roksund Hov
Johannes Roksund Hov
TKTom H Karlsen
Tom H Karlsen
Tom Karlsen and colleagues report an association study for primary sclerosing cholangitis (PSC), a severe liver disease, using the Immunochip array. They identify nine loci newly associated with PSC and examine pleiotropy with other autoimmune disorders. Primary sclerosing cholangitis (PSC) is a severe liver disease of unknown etiology leading to fibrotic destruction of the bile ducts and ultimately to the need for liver transplantation1,2,3. We compared 3,789 PSC cases of European ancestry to 25,079 population controls across 130,422 SNPs genotyped using the Immunochip4. We identified 12 genome-wide significant associations outside the human leukocyte antigen (HLA) complex, 9 of which were new, increasing the number of known PSC risk loci to 16. Despite comorbidity with inflammatory bowel disease (IBD) in 72% of the cases, 6 of the 12 loci showed significantly stronger association with PSC than with IBD, suggesting overlapping yet distinct genetic architectures for these two diseases. We incorporated association statistics from 7 diseases clinically occurring with PSC in the analysis and found suggestive evidence for 33 additional pleiotropic PSC risk loci. Together with network analyses, these findings add to the genetic risk map of PSC and expand on the relationship between PSC and other immune-mediated diseases.

1 November 2016 in Cell
Verified
Journal Article
Closed access
YLYang Li
Yang Li
MOMarije Oosting
Marije Oosting
SSSanne P. Smeekens
Sanne P. Smeekens
MJmartin Jaeger
martin Jaeger
RARaul Aguirre-Gamboa
Raul Aguirre-Gamboa
MNMihai G. Netea
Mihai G. Netea

14 June 2014 in Diabetes
Verified
Journal Article
Open access
PDF file
HKHenna Kallionpää
Henna Kallionpää
LELaura L. Elo
Laura L. Elo
ELEssi Laajala
Essi Laajala
JMJuha Mykkänen
Juha Mykkänen
IRIsis Ricaño-Ponce
Isis Ricaño-Ponce
RLRiitta Lahesmaa
Riitta Lahesmaa
The insult leading to autoantibody development in children who will progress to develop type 1 diabetes (T1D) has remained elusive. To investigate the genes and molecular pathways in the pathogenesis of this disease, we performed genome-wide transcriptomics analysis on a unique series of prospective whole-blood RNA samples from at-risk children collected in the Finnish Type 1 Diabetes Prediction and Prevention study. We studied 28 autoantibody-positive children, out of which 22 progressed to clinical disease. Collectively, the samples covered the time span from before the development of autoantibodies (seroconversion) through the diagnosis of diabetes. Healthy control subjects matched for date and place of birth, sex, and HLA-DQB1 susceptibility were selected for each case. Additionally, we genotyped the study subjects with Immunochip to identify potential genetic variants associated with the observed transcriptional signatures. Genes and pathways related to innate immunity functions, such as the type 1 interferon (IFN) response, were active, and IFN response factors were identified as central mediators of the IFN-related transcriptional changes. Importantly, this signature was detected already before the T1D-associated autoantibodies were detected. Together, these data provide a unique resource for new hypotheses explaining T1D biology.

4 July 2016 in Nature Medicine
Verified
Journal Article
Closed access
PDF file
YLYang Li
Yang Li
MOMarije Oosting
Marije Oosting
PDPatrick Deelen
Patrick Deelen
IRIsis Ricaño-Ponce
Isis Ricaño-Ponce
SSSanne Smeekens
Sanne Smeekens
MNMihai G. Netea
Mihai G. Netea

1 May 2017 in Cell Reports
Verified
Journal Article
Open access
STSubhash Kumar Tripathi
Subhash Kumar Tripathi
ZCZhi Jane Chen
Zhi Jane Chen
ALAntti Larjo
Antti Larjo
KKKartiek Kanduri
Kartiek Kanduri
KNKari Nousiainen
Kari Nousiainen
RLRiitta Lahesmaa
Riitta Lahesmaa
The development of therapeutic strategies to combat immune-associated diseases requires the molecular mechanisms of human Th17 cell differentiation to be fully identified and understood. To investigate transcriptional control of Th17 cell differentiation, we used primary human CD4+ T cells in small interfering RNA (siRNA)-mediated gene silencing and chromatin immunoprecipitation followed by massive parallel sequencing (ChIP-seq) to identify both the early direct and indirect targets of STAT3. The integrated dataset presented in this study confirms that STAT3 is critical for transcriptional regulation of early human Th17 cell differentiation. Additionally, we found that a number of SNPs from loci associated with immune-mediated disorders were located at sites where STAT3 binds to induce Th17 cell specification. Importantly, introduction of such SNPs alters STAT3 binding in DNA affinity precipitation assays. Overall, our study provides important insights for modulating Th17-mediated pathogenic immune responses in humans.